Clincosm LogoSign in Get a demo

her2 positive metastatic breast cancer

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2 Positive Metastatic Breast Cancer Trial in Worldwide (ARX788)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Glendale, California
  • +52 more
Oct 25, 2022

HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Beijing, China
    307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022

HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (inetetamab and PD-1 inhibitor combined with chemo.)

Recruiting
  • HER2 Positive Metastatic Breast Cancer
  • inetetamab and PD-1 inhibitor combined with chemotherapy.
  • Zhengzhou, Henan, China
    Henan cancer hospital
Aug 2, 2022

HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib plus Capecitabine)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Pyrotinib plus Capecitabine
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 9, 2021

HER2 Positive Metastatic Breast Cancer Trial in Beijing, Shijiazhuang, Zhengzhou (Margetuximab Margetuximab-IV)

Completed
  • HER2 Positive Metastatic Breast Cancer
  • Margetuximab Margetuximab-IV
  • Beijing, Beijing, China
  • +2 more
Jun 11, 2021

HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, Lapatinib, capecitabine)

Unknown status
  • HER2 Positive Metastatic Breast Cancer
  • Beijing, Beijing, China
  • +1 more
Jul 5, 2018

Her2 Positive Metastatic Breast Cancer Trial in Ireland (non-pegylated liposomal doxorubicon (Myocet™), Lapatinib (Tyverb™))

Terminated
  • Her2 Positive Metastatic Breast Cancer
  • non-pegylated liposomal doxorubicon (Myocet™)
  • Lapatinib (Tyverb™)
  • Cork, Ireland
  • +9 more
Oct 23, 2015